1. Introduction
===============

Endometrial cancer (ECa) is one of the most common gynecological malignancies. It constitutes 6% of total cancers affecting women worldwide \[[@b1-ijms-13-09489]\]. The diagnosis of ECa is very dependent on endometrial biopsy, which is invasive and highly subjective. As such, ECa is difficult to diagnose, particularly at the early stage of the malignancy. Up until now, no tumor marker has been established specifically for ECa, even though several serum markers that are known to be non-specific are currently being applied for its diagnosis \[[@b2-ijms-13-09489]\]. Identification of proteins that are differentially expressed in the urine of ECa patients at an early stage may facilitate the development of a method to efficiently diagnose ECa non-invasively. These markers not only assist in the early and accurate identification of ECa patients, which is important for the patients' survival, but also make the invasive biopsy procedure unnecessary for non-ECa patients.

Urine has become one of the attractive biofluids to screen for potential protein biomarkers. It promises a convenient method of disease detection and monitoring because it can be easily and noninvasively obtained from the patients. Urinary protein biomarkers have been reported to be used for the detection of cancers of the kidney, bladder and prostate \[[@b3-ijms-13-09489]\]. One of the more recent and popular methods used to screen for the possible presence of potential biomarkers in the urine involves the proteomics technology \[[@b4-ijms-13-09489],[@b5-ijms-13-09489]\]. When subjected to two-dimensional gel electrophoresis (2-DE), urinary proteins may be profiled on the basis of the differences in isoelectric point and molecular weight. These proteins may also be quantified by densitometry and identified using mass spectrometry and database searches. Since urine usually harbors hydrophilic molecules in the form of glycoproteins, lectins may be additionally employed in the proteomics method to specifically target the presence of proteins with specific oligosaccharide structures.

In the present study, the urine of patients who were newly diagnosed with ECa and control subjects was analyzed using 2-DE, densitometry and tandem mass spectrometry to screen for proteins that are differentially expressed. Aside from the conventional gel-based proteomics approach, a lectin that binds to the *O*-glycans of glycoproteins was also used to specifically profile the *O*-glycoproteins in the urine of the ECa patients and control subjects. Many *O*-glycoproteins had previously been implicated with cancer \[[@b6-ijms-13-09489]--[@b9-ijms-13-09489]\]. Hence, this lectin was chosen because it specifically binds to the oligosaccharide moieties of *O*-glycoproteins \[[@b10-ijms-13-09489],[@b11-ijms-13-09489]\].

2. Results
==========

2.1. Profiling of Urinary Proteins by 2-DE
------------------------------------------

Comparable 2-DE urine protein profiles of patients with ECa and control subjects were obtained when their urinary protein samples were subjected to 2-DE followed by silver staining. [Figure 1](#f1-ijms-13-09489){ref-type="fig"} shows representative urine proteome maps of the controls (panel A) and ECa patients (panel B). Seven protein clusters appeared to be consistently resolved in all the 2-DE maps of the patients and controls. When subjected to the MALDI-ToF MS/MS analysis, the protein clusters were identified as kininogen 1 (KNG), alpha-1 acid glycoprotein (AAG), zinc alpha-2 glycoprotein (ZAG), CD59, protein AMBP (AMBP), Ig gamma 3 chain C region (IgG3C) and Ig kappa chain C region (IgKC). [Table 1](#t1-ijms-13-09489){ref-type="table"} shows the mass spectrometric identification data of the urinary proteins that were resolved by 2-DE.

2.2. Image Analysis of 2-DE Separated Urinary Proteins
------------------------------------------------------

When image analysis was performed using the Image Master 2D Platinum Software version 7.0, it was apparent that the levels of the proteins detected in the urine of ECa patients were comparable to those of the controls, except for AAG, ZAG and CD59. The intensities of AAG and ZAG were more than 10-fold higher in the patients' proteome map, whilst the CD59 protein cluster was barely detected in the 2-DE profiles of the patients' urine samples. [Table 2](#t2-ijms-13-09489){ref-type="table"} demonstrates the average percentage of volume contribution of the seven detected urinary proteins.

2.3. Profiling of Urinary *O*-Glycoproteins
-------------------------------------------

To exclusively target the *O*-glycoproteins in the urine samples, 2-DE separated urinary proteins were transferred onto a nitrocellulose membrane and probed with enzyme-conjugated CGB lectin. The 2-DE membrane profiles that were developed using the CGB lectin were entirely different from those generated by silver staining ([Figure 2](#f2-ijms-13-09489){ref-type="fig"}). Six clusters of *O*-glycoproteins were consistently detected in the urinary membrane profiles. In addition, one *O*-glycoprotein spot, with a molecular mass of approximately 51 kDa, seemed to appear in the profiles of all the control samples that were analyzed but faintly appeared in only one of the urine samples from patients with ECa. When the membrane profiles were subjected to image analysis, the levels of all urinary *O*-glycoproteins appeared comparable between the ECa patients and the controls except for the 51 kDa protein spot, which was 10.6-fold higher in the controls compared to the ECa patients ([Table 3](#t3-ijms-13-09489){ref-type="table"}, panel A). To identify the sole aberrantly expressed urinary *O*-glycoprotein, the spot was excised and subjected to on-membrane trypsin digestion and analyzed by mass-spectrometry. Panel B of [Table 3](#t3-ijms-13-09489){ref-type="table"} demonstrates the MS/MS data obtained, which identified the *O*-glycoprotein spot as that of nebulin, when a database search was performed.

2.4. Immobilized CGB Lectin Affinity Chromatography and LC-MS/MS
----------------------------------------------------------------

To validate the data that was obtained from the Western blot-lectin analysis, pooled urinary protein samples from the ECa patients as well as those of the controls were independently subjected to CGB lectin affinity chromatography and their bound fractions were then analyzed using LC-MS/MS. Based on a minimum of 90% protein probability confidence, more than 200 peptides were considered identified, which included that of nebulin. [Table 4](#t4-ijms-13-09489){ref-type="table"} lists the *O*-glycosylated proteins that were isolated using the CGB lectin or those potentially known to be *O*-glycosylated. The nebulin peptide spectrum with the de novo sequence K.AYELQSDNVYKADLEWLRGIGWMPNDSVSVNHA.K (amino acid positions 4103--4136) apparently appeared only in the profile that was generated from the pooled control urine samples but not in that which was obtained from the pooled urine of ECa patients.

3. Discussion
=============

In the present study, the different altered levels of ZAG, AAG and CD59 were initially detected in the urine samples of patients with ECa compared to the controls. While the levels of ZAG and AAG were significantly increased, the expression of CD59 was much lower in the ECa patients. These proteins have been previously identified as potential biomarkers for various different types of cancers ([Table 5](#t5-ijms-13-09489){ref-type="table"}).

ZAG generally functions as a stimulator of lipolysis although it is also known to have other functions such as being a carrier protein, an immunoregulator and a cell adhesion molecule \[[@b15-ijms-13-09489]\]. At the same time, ZAG has also been associated with cancer, as the levels of the protein have been reported to be increased in the sera of patients with cancers of the prostate \[[@b16-ijms-13-09489]\] and cervix \[[@b7-ijms-13-09489]\]. This was postulated to be due to the changes in the levels of adipokines and estrogen in the patients. The increase in levels of ZAG in the urine of patients with ECa shown in this study may reflect the change that occurred in the serum.

A comparable trend of changes in both the serum and urine samples was also observed in the case of AAG in patients with ECa. AAG was also found to be elevated in the urine of ECa patients in this study. And other researchers have previously reported its increased levels in the serum of patients suffering from several different cancers including ECa \[[@b26-ijms-13-09489],[@b29-ijms-13-09489]\].

The decrease in the levels of CD59 in the urine of patients with bladder cancer \[[@b4-ijms-13-09489]\], pancreatic ductal adenocarcinoma \[[@b30-ijms-13-09489]\] and ovarian cancer \[[@b5-ijms-13-09489]\] has been previously reported. CD59, also known as protectin, is a cell surface molecule that functions to inhibit the membrane attack complex of the complement pathway. The data of our present study further demonstrates decreased levels of CD59 in the urine of patients with ECa. Our data is also compatible with the report on the altered expression of CD59 in malignant tissues obtained from patients with ECa \[[@b19-ijms-13-09489]\].

When similar 2-DE separated urinary proteins were transferred onto nitrocellulose membranes and probed with enzyme-conjugated CGB lectin, a different profile consisting of only *O*-glycosylated proteins was obtained. Comparative densitometry analysis of the 2-DE membrane profiles generated from patients and controls demonstrated the significant altered levels of a single *O*-glycoprotein, which was subsequently identified as a 51 kDa fragment of nebulin. The nebulin fragment spot may not be detected in the earlier 2-DE experiments probably because of its relatively low amount in the urine samples. The absence or low levels of the nebulin fragment in the urine of patients with ECa relative to the controls was further confirmed when urinary *O*-glycosylated protein fractions obtained from passing pooled urine samples to CGB lectin affinity chromatography were analyzed using LC-MS/MS.

Nebulin, a protein with a deduced molecular weight of 772.9 kDa functions as a template for polymerization of actin \[[@b31-ijms-13-09489]\]. The protein is expressed predominantly in the thin filaments of striated muscle. It is known to be glycosylated, although the precise structure of its glycan moiety has never been characterized \[[@b32-ijms-13-09489]\]. Hence, the result of the CGB lectin analyses performed in this study is a form of evidence that nebulin is *O*-glycosylated. The low molecular weight of the nebulin spot detected in the 2-DE experiments is indicative of a truncated or cleaved protein. The reduced levels of tissue nebulin are commonly associated with myopathy \[[@b33-ijms-13-09489]\]. However, its increased levels in the pancreatic juice are believed to be associated with the cellular turnover in patients with pancreatic cancer \[[@b27-ijms-13-09489]\]. To the best of our knowledge, there is no previous report on the detection of nebulin or its fragment in the urine, but the protein has been detected in other biofluids such as serum \[[@b34-ijms-13-09489]\] and pancreatic juice \[[@b27-ijms-13-09489]\].

4. Experimental Section
=======================

4.1. Urine Samples and Processing
---------------------------------

Urine samples were obtained from patients newly diagnosed with stages IB and IIA/B ECa (*n* = 7) in the morning at the Gynecological Clinic, University of Malaya Medical Centre (UMMC), Kuala Lumpur, prior to any treatment or surgery. All patients were confirmed with negative diagnosis for other diseases. [Table 6](#t6-ijms-13-09489){ref-type="table"} demonstrates the clinical data of patients involved in the study. Control urine samples (*n* = 11) were obtained randomly from age-matched healthy women. Samples were obtained with the patients' consent and approval granted by the Ethical Committee of UMMC in accordance to the ICH GCP guideline and the declaration of Helsinki. The samples were immediately added with sodium azide to a final concentration of 20 mM to inhibit any bacterial growth. To remove cells and debris, the samples were centrifuged at 10,000 rpm at 4 °C. The supernatant was collected and dialyzed against four changes of 1 L unsterile distilled water at the same temperature in order to reduce the concentration of salt, which would affect the subsequent analyses. The urine samples were aliquoted, freeze-dried and kept at −80 °C for a period of not more than a month. The protein content was determined using the Pierce BCA protein assay kit (Thermo Fisher Scientific, Rockford, USA).

4.2. Two-Dimensional Electrophoresis and Silver Staining
--------------------------------------------------------

2-DE was performed as previously reported \[[@b35-ijms-13-09489],[@b36-ijms-13-09489]\]. Briefly, 300 μg of freeze dried urine samples were solubilized and subjected to isoelectric focusing in 11 cm rehydrated precast Immobiline Drystrips pH 3--10 overnight, followed by first dimension separation with IPGphor 3 (GE Healthcare Biosciences, Uppsala, Sweden). For the second dimension separation, the focused samples in the strips were subjected to electrophoresis using 12.5% polyacrylamide gel in the presence of SDS. Silver staining of the 2-DE gels was performed based on the method described by Heukeshorven and Dernick \[[@b37-ijms-13-09489]\]. For mass spectrometry analysis, a modified silver staining method by Shevchenko *et al.*, was used \[[@b38-ijms-13-09489]\].

4.3. Image Analysis
-------------------

The silver stained 2-DE gels (as well as lectin-developed membranes in section 4.6) were scanned using ImageScanner III (GE Healthcare Bioscience, Uppsala, Sweden). Image analysis was restricted to protein spot clusters that appeared consistently within each group of urine samples. The levels of proteins in each sample were calculated as a percentage of volume contribution (% vol) in which the volume of contribution refers to the volume percentage of a protein taken against the total spot volume of all the proteins, in order to eliminate the possible variations due to staining. All values are presented as mean ± S.E.M (standard error of the mean). The Student's t-test was used to analyze the significance of difference between controls and ECa patients. A value of *p* \< 0.05 was initially accepted as significantly different. The false discovery rate control was then performed using the method of Benjamini and Hochberg \[[@b39-ijms-13-09489]\]. The *p* value was then corrected, with those \<0.0214 considered to be significantly different.

4.4. On-Membrane Digestion
--------------------------

On-membrane digestion was performed according to the method described by Luque-Garcia *et al*. \[[@b40-ijms-13-09489]\], with modifications. Briefly, the nitrocellulose membrane was blocked with 1% PVP-40 (w/v) in TBS, washed three times with the same buffer and incubated with the HRP-conjugated CGB lectin. After the development of the membrane as previously described, the protein spot was excised and destained with 0.1% EDTA dihydrate for 30 minutes. Horseradish peroxidase-conjugated CGB lectin was stripped by washing the spot with 0.5 and 1.0 M melibiose in Tris-HCl pH 7.5 for 30 minutes each. Then, the stripped spot was blocked with 0.5% (w/v) PVP-40 in 100 mM acetic acid at 37 °C for 30 minutes and digested with 12.5 ng/μL trypsin in 50 mM NH~4~HCO~3~ buffer overnight. After digestion, the sample was dissolved in acetone, vortexed and incubated for 30 minutes. The peptide was dissolved in 10 mg/mL of CHCA in 1% TFA of 50:50 ACN and MilliQ water after the removal of acetone, which contained a nitrocellulose membrane.

4.5. MALDI-ToF Mass Spectrometry
--------------------------------

Plugs of proteins of interest from the 2-DE gels were subjected to in-gel digestion as previously described \[[@b41-ijms-13-09489]\]. Identification of a protein by MALDI mass spectrometry was performed on one of the representative gels, using the Applied Biosystem 4800 Proteomics Analyzer. The mass standard kit (Applied Biosystems/MDS Sciex, Toronto, Canada) was used as the calibrator for the MS/MS analysis. The data from the MS/MS was submitted to the MASCOT search engine for protein identification.

4.6. Western Blotting and Detection by CGB Lectin
-------------------------------------------------

CGB lectin was purified from the crude extracts of the champedak seeds using immobilized galactose affinity chromatography. The purity of the lectin was confirmed using SDS-PAGE 18% polyacrylamide gel. Western blotting was performed by electrophoretically transferring 2-DE-separated urinary proteins from gels onto nitrocellulose membrane (0.45 μm) using the NovaBlot Kit of Multiphor II Electrophoresis system (GE Healthcare Bioscience, Uppsala, Sweden) at 0.8 mA/cm^2^ for 1 hour. The membrane was blocked with 3% w/v gelatin in Tris-buffered saline Tween-20 (TBST), pH7.5 for 1 hour at room temperature and washed three times with the same buffer. Detection of transferred urinary *O*-glycoproteins was performed using horseradish peroxidase-conjugated CGB lectin. Blots were developed using metal enhanced DAB substrate kit for horseradish peroxidase (Pierce, Rockford, USA).

4.7. CGB Lectin Affinity Separation and LC-MS/MS
------------------------------------------------

CGB lectin was conjugated to CNBr-activated Sepharose 4B (GE Healthcare Bioscience, Uppsala, Sweden), based on the manufacturer's instructions. Column was equilibrated with PBS, pH 7.2, prior to the application of pooled urinary proteins (400 μg). Eluted fractions were monitored by measurement of absorbance at 280 nm. Elution of urinary *O*-glycoproteins was performed using 0.5 M of D-melibiose in PBS. Bound fractions collected from both columns were pooled, dialyzed and concentrated with the vivaspin column concentrator (Sartorius Stedim Biotech, Goettingen, Germany) and send to The Vincent Coates Foundation Mass Spectrometry Laboratory, Stanford University Mass Spectrometry for LC-MS/MS analysis.

5. Conclusions
==============

In summary, the data of this study is suggestive of the potential use of urinary ZAG, AAG, CD59 and a 51 kDa fragment of nebulin as complementary biomarkers for ECa. However, this requires further extensive validation in a study that has to be carried out on clinically representative populations. Such a study cannot be possibly performed using the present gel- and lectin-based proteomics analyses. Nevertheless, with the identification of the potential urinary biomarkers in the present study, validation is easily carried out in a large-scale investigation using assays like the ELISA.
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![Typical two-dimensional gel electrophoresis (2-DE) urinary protein profiles. The labeled spot clusters are proteins which consistently appeared in profiles of control subjects. Panels (**A**) and (**B**) refer to the profiles of a control subject and a patient with stage IB endometrial cancer (ECa), respectively.](ijms-13-09489f1){#f1-ijms-13-09489}

![Typical 2-DE urinary *O*-glycoprotein profiles. Panels (**A**) and (**B**) refer to 2-DE urinary *O*-glycoprotein profiles of a control subject and a patient with stage IB ECa, respectively. Spot clusters that are marked in boxes are proteins, which were consistently detected by CGB lectin. NEB refers to nebulin. The acidic side of the membranes is to the left and the relative molecular mass declines from the top.](ijms-13-09489f2){#f2-ijms-13-09489}

###### 

Mass spectrometric identification of 2-DE separated urinary proteins.

  Protein Entry Name [+](#tfn1-ijms-13-09489){ref-type="table-fn"}   Protein Name           Accession Number [\#](#tfn2-ijms-13-09489){ref-type="table-fn"}   Nominal Mass (kDa)/p*I*   MOWSE Protein Score   Sequence Coverage (%)
  ------------------------------------------------------------------ ---------------------- ----------------------------------------------------------------- ------------------------- --------------------- -----------------------
  **KNG**                                                            Kininogen              P01042                                                            71/6.34                   68                    7
  **IGHG3**                                                          Ig g3 chain C region   P01860                                                            41/8.46                   16                    3
  AAG                                                                α1-acid glycoprotein   P19652                                                            23/5.03                   241                   16
  ZAG                                                                Zinc α2 glycoprotein   P25311                                                            33/5.57                   134                   20
  AMBP                                                               Protein AMBP           P02760                                                            39/5.95                   50                    12
  IGKC                                                               Ig l1 chain C region   P01834                                                            11/5.58                   141                   32
  CD59                                                               CD59 glycoprotein      P13987                                                            14/6.02                   121                   18

Protein entry names are from the UniProtKB database \[[@b12-ijms-13-09489]\].

Accession numbers are from the Mascot search engine \[[@b13-ijms-13-09489]\].

###### 

Mean percentage of volume contribution of urinary proteins.

  Urinary Proteins   Mean % Vol ± SEM   *p*              Fold Changes [\*](#tfn3-ijms-13-09489){ref-type="table-fn"}   
  ------------------ ------------------ ---------------- ------------------------------------------------------------- -------
  AAG                0.161 ± 0.072      2.746 ± 0.717    0.001                                                         +17.1
  ZAG                0.175 ± 0.045      2.184 ± 0.592    0.001                                                         +12.5
  CD59               2.575 ± 0.497      0.177 ± 0.070    0.002                                                         −14.6
  KNG                5.137 ± 1.826      0.945 ± 0.491    0.108                                                         ns
  IGKC               14.785 ± 2.197     18.840 ± 2.651   0.286                                                         ns
  AMBP               8.941 ± 1.706      12.837 ± 3.430   0.306                                                         ns
  IGHG3              4.014 ± 1.221      4.554 ± 1.706    0.807                                                         ns

Fold expression changes are relative to the control values; (+) increase in expression; (−) decrease in expression; ns -- not statistically significant; A *p-*value of less than 0.0214 was considered significant.

###### 

Relative expression (A) and identification of nebulin (B).

  \(A\)     Mean % Vol ± SEM            *p*                           Fold Changes              
  --------- --------------------------- ----------------------------- ------------------------- --------------------------------------------------
            1.08 ± 0.172                0.102 ± 0.095                 0.001                     −10.6
                                                                                                
  **(B)**   **Accession Number ^\#^**   **Nominal Mass (kDa)/p*I***   **MOWSE Protein Score**   **Sequence Coverage (%)**
                                                                                                
            P20929                      775/9.11                      64                        1 [\*](#tfn4-ijms-13-09489){ref-type="table-fn"}

relative to native nebulin molecule.

###### 

List of *O*-glycosylated/potentially *O*-glycosylated proteins isolated using CGB lectin.

  Protein Name                                                 Accession Number   Subcellular Location   Glycan [\#](#tfn5-ijms-13-09489){ref-type="table-fn"}
  ------------------------------------------------------------ ------------------ ---------------------- -------------------------------------------------------
  Protein AMBP                                                 P02760             Secreted               *O*-linked
  ATP synthase subunit beta, mitochondrial                     P24539             Membrane               Potential *O*-linked
  Serotransferrin                                              P02787             Secreted               *O*-linked
  Transmembrane protein 110                                    Q86TLZ             Membrane               Potential *O*-linked
  Phosphoinositide-3 kinase interacting protein 1              Q96FE7             Membrane               *O*-linked
  Ribonuclease pancreatic                                      P07998             Secreted               Potential *O*-linked
  Prostaglandin-H2-D isomerase                                 P41222             Secreted               Potential *O*-linked
  Membrane bound transcription factor site-1 protease          Q14703             Membrane               Potential *O*-linked
  Homeobox protein engrailed 2                                 P19622             Nucleus                Potential *O*-linked
  Actin, cytoplasmic 1                                         P60709             Cytoplasmic            Potential *O*-linked
  Neurofilament medium polypeptide                             P07197             Cytoplasmic            *O*-linked
  CD55 decay-accelerating factor splicing variant 4            Q14UF3             Membrane               Potential *O*-linked
  Leucine rich alpha 2 glycoprotein                            P02750             Secreted               *O*-linked
  Spondin-2                                                    Q9BUD6             Secreted               Potential *O*-linked
  Protein RRP5 homolog                                         Q14690             Nucleus                Potential *O*-linked
  CD44 antigen                                                 P16070             Membrane               *O*-linked
  Phosphatidylinositol-3,4,5-triphosphate 5-phosphatase-1      Q92835             Membrane               Potential *O*-linked
  Solute carrier family 12 member 6                            Q9UHW9             Membrane               Potential *O*-linked
  Mucin-5B                                                     Q9HC84             Secreted               *O*-linked
  Major facilitator superfamily domain containing protein 10   Q14728             Membrane               Potential *O*-linked
  PDZ and LIM domain protein 5                                 Q96HC4             Membrane               Potential *O*-linked
  Leukocyte associated immunoglobulin-like receptor 1          Q6GTX8             Membrane               Potential *O*-linked
  Tumor necrosis receptor superfamily member 16                P08138             Membrane               Potential *O*-linked
  Lipocalin-1                                                  P31025             Secreted               Potential *O*-linked
  Amyloid beta A4                                              P05067             Membrane               *O*-linked
  Nebulin                                                      P20929             Cytoplasmic            Potential *O*-linked
  Transcription factor HES-2                                   Q9Y543             Nucleus                Potential *O*-linked
  Rho GTPase-activating protein 12                             P20936             Cytoplasmic            Potential *O*-linked
  Solute carrier family 13 member 3                            Q8WWT9             Membrane               Potential *O*-linked
  Sodium/bile acid contransporter                              Q14973             Membrane               Potential *O*-linked
  Bromodomain-containing protein 3                             Q15059             Nucleus                Potential *O*-linked
  Inter alpha trypsin inhibitor heavy chain H4                 Q14624             Secreted               *O*-linked
  Ig gamma-1 chain C region                                    P01857             Secreted               Potential *O*-linked
  Ig gamma-2 chain C region                                    P01859             Secreted               Potential *O*-linked
  Ig alpha-1 chain C region                                    P01876             Unknown                *O*-linked
  Ig lambda-1 chain C region                                   P0CG04             Unknown                Potential *O*-linked

Types of glycan as annotated by UniProt; glycosylation potential was determined by NetOGlyc 3.1 \[[@b14-ijms-13-09489]\].

###### 

Identification of CD59, ZAG, AAG and NEB as potential biomarkers. Check this table.

  Protein   Type of Cancer   Sample Type             Reference
  --------- ---------------- ----------------------- --------------------------
  CD59      Oral             Saliva                  \[[@b17-ijms-13-09489]\]
            Lung             Urine                   \[[@b18-ijms-13-09489]\]
            Ovarian          Urine                   \[[@b5-ijms-13-09489]\]
            Endometrial      Tissue                  \[[@b19-ijms-13-09489]\]
                                                     
  ZAG       Breast           Tissue                  \[[@b20-ijms-13-09489]\]
            Hepatocellular   Tissue                  \[[@b21-ijms-13-09489]\]
            Prostate         Tissue and serum        \[[@b16-ijms-13-09489]\]
            Cervical         Serum                   \[[@b7-ijms-13-09489]\]
                                                     
  AAG       Breast           Nipple aspirate fluid   \[[@b22-ijms-13-09489]\]
            Colon            Plasma                  \[[@b23-ijms-13-09489]\]
            Hepatocellular   Serum                   \[[@b24-ijms-13-09489]\]
            Ovarian          Serum                   \[[@b25-ijms-13-09489]\]
            Endometrial      Serum                   \[[@b26-ijms-13-09489]\]
                                                     
  NEB       Pancreatic       Pancreatic juice        \[[@b27-ijms-13-09489]\]
            Gastric          Tissue                  \[[@b28-ijms-13-09489]\]

###### 

Clinical data of ECa patients involved in the study.

  ECa Patient   Stage   Estrogen or Tamoxifen Treatment   Obesity   Late Menopause   Previous Pregnancy   Early Puberty   Blood Creatinine Level
  ------------- ------- --------------------------------- --------- ---------------- -------------------- --------------- ------------------------
  1             IB      No                                No        Yes              Yes                  No              Normal
  2             IB      No                                No        Yes              Yes                  No              Normal
  3             IB      No                                No        No               Yes                  No              Normal
  4             IB      No                                No        No               Yes                  No              Normal
  5             IB      No                                No        No               Yes                  No              Normal
  6             IIA     No                                Yes       No               Yes                  No              Normal
  7             IIB     No                                No        No               No                   No              Normal
